Preexisting Serum Autoantibodies Against the NMDAR Subunit NR1 Modulate Evolution of Lesion Size in Acute Ischemic Stroke

Stroke. 2015 May;46(5):1180-6. doi: 10.1161/STROKEAHA.114.008323. Epub 2015 Mar 12.

Abstract

Background and purpose: Recently, we reported high seroprevalence (age-dependent up to >19%) of N-methyl-d-aspartate-receptor subunit NR1 (NMDAR1) autoantibodies in both healthy and neuropsychiatrically ill subjects (N=4236). Neuropsychiatric syndrome relevance was restricted to individuals with compromised blood-brain barrier, for example, apolipoprotein E4 (APOE4) carrier status, both clinically and experimentally. We now hypothesized that these autoantibodies may upon stroke be protective in individuals with hitherto intact blood-brain barrier, but harmful for subjects with chronically compromised blood-brain barrier.

Methods: Of 464 patients admitted with acute ischemic stroke in the middle cerebral artery territory, blood for NMDAR1 autoantibody measurements and APOE4 carrier status as indicator of a preexisting leaky blood-brain barrier was collected within 3 to 5 hours after stroke. Evolution of lesion size (delta day 7-1) in diffusion-weighted magnetic resonance imaging was primary outcome parameter. In subgroups, NMDAR1 autoantibody measurements were repeated on days 2 and 7.

Results: Of all 464 patients, 21.6% were NMDAR1 autoantibody-positive (immunoglobulin M, A, or G) and 21% were APOE4 carriers. Patients with magnetic resonance imaging data available on days 1 and 7 (N=384) were divided into 4 groups according to NMDAR1 autoantibody and APOE4 status. Groups were comparable in all stroke-relevant presenting characteristics. The autoantibody+/APOE4- group had a smaller mean delta lesion size compared with the autoantibody-/APOE4- group, suggesting a protective effect of circulating NMDAR1 autoantibodies. In contrast, the autoantibody+/APOE4+ group had the largest mean delta lesion area. NMDAR1 autoantibody serum titers dropped on day 2 and remounted by day 7.

Conclusions: Dependent on blood-brain barrier integrity before an acute ischemic brain injury, preexisting NMDAR1 autoantibodies seem to be beneficial or detrimental.

Keywords: apolipoprotein E4; blood–brain barrier; immunoglobulin class.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Apolipoprotein E4 / genetics
  • Autoantibodies / analysis*
  • Blood-Brain Barrier / immunology
  • Blood-Brain Barrier / pathology
  • Brain Ischemia / pathology*
  • Disease Progression
  • Female
  • Heterozygote
  • Humans
  • Infarction, Middle Cerebral Artery / pathology
  • Intracranial Hemorrhages / etiology
  • Male
  • Middle Aged
  • Prospective Studies
  • Receptors, N-Methyl-D-Aspartate / immunology*
  • Seroepidemiologic Studies
  • Stroke / pathology*
  • Treatment Outcome

Substances

  • Apolipoprotein E4
  • Autoantibodies
  • NR1 NMDA receptor
  • Receptors, N-Methyl-D-Aspartate